<DOC>
	<DOCNO>NCT02549963</DOCNO>
	<brief_summary>This prospective , multi-center , randomize , pilot study compare WATCHMAN leave atrial appendage occlusion device Rivaroxaban therapy patient non-valvular atrial fibrillation .</brief_summary>
	<brief_title>Evaluation WATCHMAN Left Atrial Appendage Occlusion Device Patients With Atrial Fibrillation Versus Rivaroxaban</brief_title>
	<detailed_description />
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Anticoagulants</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<criteria>Paroxysmal , persistent permanent nonvalvular atrial fibrillation Eligible LAAO longterm rivaroxaban therapy Calculated CHA2DS2VASc score 2 great . Contraindicated/allergic aspirin , clopidogrel novel oral anticoagulant . Indicated clopidogrel therapy take clopidogrel within 7 day prior enrollment . History atrial septal repair atrial septal defect/patent foramen ovale device . History valvular heart disease . Implanted mechanical valve prosthesis . New York Heart Association Class IV congestive heart failure leave ventricular ejection fraction le 30 % . Patient leave atrial/left atrial appendage thrombus screen echocardiography Platelet &lt; 100*109/L hemoglobin &lt; 100g/L Expected lifespan le 1 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>